<PAGE>
Exhibit 99.1
Press Release of the Registrant
Contact:
---------
Mark R. Vincent
---------------
Director, Corporate Communications
& Investor Relations
[email protected]
CuraGen Corporation
1-888-GENOMICS
www.curagen.com
---------------
FOR IMMEDIATE RELEASE
---------------------
CuraGen Corporation Offering 4 Million Shares of Its Common Stock
New Haven, CT -- November 6, 2000 -- CuraGen Corporation (Nasdaq: CRGN), an
integrated genomics based drug discovery and development company, announced
today that it is making a public offering of 4 million newly issued shares of
its common stock, plus up to 600,000 additional shares to cover any over-
allotments. All shares of the common stock are being offered by the Company.
The shares of common stock are being offered through a prospectus supplement
pursuant to the Company's effective shelf registration statement in an offering
jointly lead-managed by Morgan Stanley Dean Witter and Lehman Brothers, and co-
managed by Dain Rauscher Wessels; Bear, Stearns & Co. Inc.; Prudential Vector
Healthcare, a unit of Prudential Securities; and Thomas Weisel Partners LLC. A
copy of the prospectus related to the offering can be obtained from Morgan
Stanley Dean Witter at 1585 Broadway, New York, NY 10036, (212) 761-4000.
This press release shall not constitute an offer to sell or the solicitation of
an offer to buy, nor shall there be any sale of these securities in any state in
which such offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such state. A shelf
registration statement relating to the shares that the Company intends to sell
has previously been filed with, and declared effective by, the Securities and
Exchange Commission. Any offer, if at all, will be made only by means of a
prospectus, including a prospectus supplement, forming a part of the effective
registration statement.
CuraGen Corporation is advancing the discovery and development of pharmaceutical
and life science products through the systematic application of genomics.
CuraGen's fully integrated, Internet-based functional genomic technologies,
services, and information systems are designed to rapidly generate comprehensive
information about genes, human genetic variations, gene expression, protein
expression, protein pathways, and potential drugs that affect these pathways.
The Company is applying this comprehensive functional genomics platform to
develop protein and antibody drugs, and to identify small molecule drug targets.
CuraGen has conducted research for collaborators including Abgenix, Biogen, COR
Therapeutics, Dupont/Pioneer Hi-Bred International, Gemini Genomics, Genentech,
Glaxo Wellcome, Hoffmann-La Roche, Ono Pharmaceuticals, and Roche Vitamins.
CuraGen employs over 300 people and is headquartered in New Haven, CT.
1
